Humira (adalimumab) / AbbVie 
Welcome,         Profile    Billing    Logout  
 200 Diseases   192 Trials   192 Trials   21170 News 


«12...169170171172173174175176177178179...224225»
  • ||||||||||  TRENDS IN COMMON LABORATORY MARKERS DURING PREGNANCY IN WOMEN WITH QUIESCENT IBD. () -  Jan 28, 2020 - Abstract #DDW2020DDW_2179;    
    Abnormal changes in routinely monitored biomarkers of active inflammation are commonly observed during pregnancy even in women with quiescent IBD. Such findings suggest these changes are common physiologic responses to pregnancy and should be interpreted in the context of clinical symptoms.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    EARLY DISCONTINUATION OF ADALIMUMAB THERAPY IN IBD PREGNANCY () -  Jan 28, 2020 - Abstract #DDW2020DDW_2158;    
    The mean age at delivery was similar within the two groups (29.1 +/-5.1 vs 29.7 +/-4.5, p=0.16). More frequently, the women in the Late ADA group were primigravida (50.86 vs 35.21, p=0.001but co-morbidities score (Charlson score) did not significantly differ within groups.
  • ||||||||||  PATIENT ATTITUDES REGARDING CONTINUATION AND DE-ESCALATION OF BIOLOGIC THERAPY () -  Jan 28, 2020 - Abstract #DDW2020DDW_2130;    
    Male gender, lower educational level and literacy on IBD/biologics, non-Caucasian race and infliximab use predicted consideration of biologic discontinuation. Further studies are needed to assess if personalized counselling would alter perceptions.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
    PRIMARY BIOLOGIC-COMBINATION THERAPY IS SUPERIOR COMPARED TO CONVENTIONAL THERAPY IN NEWLY DIAGNOSED CROHN'S DISEASE IN AN INTERNATIONAL INCEPTION COHORT () -  Jan 28, 2020 - Abstract #DDW2020DDW_2071;    
    Treatment with corticosteroids without start of maintenance therapy (group 1) was started in 37 patients, an immunomodulator (azathioprine, mercaptopurine or methotrexate; group 2) in 91 patients, biological monotherapy (infliximab, adalimumab or vedolizumab; group 3) in 27 patients, and biological therapy in combination with an immunomodulator (group 4) in 27 patients. These data from a real-world international cohort seem to show superior treatment survival in newly diagnosed CD patients receiving primary treatment with biologicals (as mono- and combination therapy) and direct surgery compared to patients receiving first-line treatment with immunomodulators alone.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    IMPACT OF A PATIENT SUPPORT PROGRAM ON INFLAMMATORY BOWEL DISEASE-RELATED HOSPITALIZATION IN PATIENTS TREATED WITH ADALIMUMAB () -  Jan 28, 2020 - Abstract #DDW2020DDW_2067;    
    These data from a real-world international cohort seem to show superior treatment survival in newly diagnosed CD patients receiving primary treatment with biologicals (as mono- and combination therapy) and direct surgery compared to patients receiving first-line treatment with immunomodulators alone. IBD patient enrollment in the ADA PSP was associated with a 19% lower risk of IBD-related hospitalization, with a stronger association among biologic-naïve patients and those with UC
  • ||||||||||  Enrollment closed, Enrollment change, Trial completion date:  AJIBIOREM: Treatment Tapering in JIA With Inactive Disease (clinicaltrials.gov) -  Jan 28, 2020   
    P3,  N=62, Active, not recruiting, 
    This change in B cells could affect antibody formation and potentially explain the mechanism behind the superiority of combination therapy through the impact of thiopurines on PK of anti-TNFs. Recruiting --> Active, not recruiting | N=230 --> 62 | Trial completion date: May 2021 --> Sep 2020
  • ||||||||||  methylprednisolone oral / Generic mfg., Humira SC (adalimumab/hyaluronidase) / AbbVie, Halozyme, Humira (adalimumab) / Eisai, AbbVie
    Biomarker, Journal:  Testicular ischemia in deficiency of adenosine deaminase 2 (DADA2). (Pubmed Central) -  Jan 22, 2020   
    The phenotype of DADA2 continues to expand, and we add testicular infarction to the features of DADA2. CRP and SAA cannot be relied on as reliable biomarkers to predict tissue ischaemia and hence who to target for anti-TNFα therapy in DADA2, since these remained steadfastly normal before, during, and after testicular infarction in this case.
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
    Journal:  National trends in prescription drug expenditures and projections for 2019. (Pubmed Central) -  Jan 21, 2020   
    These estimates are at the national level. Health-system pharmacy leaders should carefully examine local drug utilization patterns to determine their own organization's anticipated spending in 2019.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    T-cell-rich B-cell lymphoma presents as Numb Chin Syndrome () -  Jan 21, 2020 - Abstract #AAN2020AAN_3107;    
    In addition, ankylosing spondylitis has been associated with increased incidence of lymphomas2. The concern for malignancy should be further heightened in patients with mental neuropathy and ankylosing spondylitis thus requiring a complete and expeditious evaluation.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Melkersson-Rosenthal Syndrome with Hearing Impairment. () -  Jan 21, 2020 - Abstract #AAN2020AAN_1875;    
    During the first episode symptoms completely resolved and the patient was in remission for 10 years. During recent episode she has residual right upper lip swelling and hearing impairment inspite of oral steroid treatment .
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie, cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Granulomatosis with Polyangiitis-Associated Hypertrophic Pachymeningitis as a Neurosarcoidosis Mimic () -  Jan 21, 2020 - Abstract #AAN2020AAN_1718;    
    Some studies suggest that C-ANCA positive HP should be recognized as a distinct clinical entity known as CNS-limited GPA, with lesions limited to the dura mater and upper airways. It is important to recognize severe headache and HP as presenting symptoms of CNS-limited GPA since early treatment with rituximab or cyclophosphamide leads to improved clinical outcome and lower relapse rate.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Rare Case of Neuro-Behçet’s Syndrome in an Adult Male . () -  Jan 21, 2020 - Abstract #AAN2020AAN_1545;    
    It is important to recognize severe headache and HP as presenting symptoms of CNS-limited GPA since early treatment with rituximab or cyclophosphamide leads to improved clinical outcome and lower relapse rate. We report an unusual case of neuro-Behçet’s syndrome in an adult male with marked spinal cord, cerebellar, medullary and pontine abnormalities, as well as worsening lower extremity weakness, upper motor neuron signs, and extensive atrophy of the spinal cord, despite aggressive immunomodulatory treatment.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Steroid-sparing agents for the treatment of inflammation in complicated neurocysticercosis () -  Jan 21, 2020 - Abstract #AAN2020AAN_1159;    
    We describe 3 cases of persistent neurocysticercosis-associated inflammation that highlight both the efficacy and complications of SSAs use in neurocysticercosis. Our series emphasizes the need for further study on the use of SSAs in the treatment of neurocysticercosis-related inflammation.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
    Retrospective data, Review, Journal:  Efficacy and safety of systemic treatments in psoriatic arthritis. A systematic review, meta-analysis and GRADE evaluation. (Pubmed Central) -  Jan 17, 2020   
    Besides the established treatment of anti TNF antibodies und ustekinumab for psoriatic arthritis, the newer treatment options of IL17 antibodies and apremilast are also effective for the treatment of psoriatic arthritis. Based on just one comparative trial and one drug each, the new class of anti IL 17 antibodies appears to be equally effective as the group of anti TNF antibodies, for apremilast this is yet unclear.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
    Clinical, Journal:  Type I leucocyte adhesion deficiency in Yemenian family managed with appropriate treatment: a case series. (Pubmed Central) -  Jan 17, 2020   
    Its diagnosis is extremely important from the management perspective, as treating these patients without adequate antibiotic cover may be fatal, as happened to one of our patient, and these patients often require hematopoietic stem cell transplantation for permanent cure. Therefore, genetic counseling especially in population with high consanguinity is mandatory.